UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2002
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Colorado
----------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-21271 84-1330732
--------------------- -----------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
1508 Brookhollow Drive, Suite 354, Santa Ana, California 92705
-----------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code) - (714) 429-7807
----------------------------------------------------------------------
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS
A press release regarding departure of the officers of the Company was issued on
October 31, 2002, a copy of which is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS
99.1 Press Release dated October 31, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SANGUI BIOTECH INTERNATIONAL, INC.
Dated: November 5, 2002 By: /s/ Wolfgang Barnikol
---------------------------------
Wolfgang Barnikol
President and CEO
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
99.1 Press Release dated October 31, 2002.
EXHIBIT 99.1
For immediate release
SANGUI BIOTECH DIRECTOR RESIGNS
Sta. Ana, California. - Edgar Fritschi, VM.D., has resigned from his positions
as Director and Member of the Board of Sangui BioTech International Inc., and
any other position he held in the Sangui Group. He declared that for personal
reasons he intends to enhance his focus on different activities while being
available for ongoing advice. The Board thanked Edgar Fritschi for his
persistent efforts to promote Sangui's future through advice and intensive
contact with industry partners. Sangui Board and management continue to pursue
the refocussing program aimed at cost reduction and fast market entry.
Shareholders are encouraged to submit proposals for the upcoming shareholders'
meeting before November 11th, 2002.
Contact:
Sangui BioTech International, Inc., SanguiBioTech AG - Prof. Dr. Dr. W.
Barnikol, CEO 049-(0)2302-915204 (Fon) 049-(0)2302-915191 (Fax), info@sangui.de
or barnikol@sangui.de or 001-714-429-4807 (Fon) 001-714-429-7808 (Fax)
http://www.sangui.de
This news release includes statements, other than historical fact, that may be
deemed forward-looking. These statements may be accompanied by words such as
"believe," "estimate," "project," "expect," "anticipate," or "predict" that
conveys the uncertainty of future events or outcomes. These statements are based
on assumptions that the Company believes are reasonable; however, many factors
could cause the Company's actual results in the future to differ materially from
the forward-looking statements made herein and in any other documents or oral
presentations made by, or on behalf of, the Company. Important factors which
could cause actual results to differ materially from those in forward-looking
statements include, among others, the ability to obtain additional financing,
which is not assured; rapid technological developments and changes; problems in
developments of the Company's products; price and product competition by
competitors; general economic conditions; and factors discussed in the Company's
SEC filings. Shareholders are cautioned that the forward-looking statements are
not guarantees of future performance and that developments different fro those
projected in the forward-looking statements can be expected. Sangui does not
intend (and is not legally obligated) to update publicly any forward-looking
statements.